• EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040

• Galderma set to commercialize EPSOLAY in the U.S. under exclusive license

Leading Acne Brand Aims to Educate Consumers and Share the Experience of Consistently Clear Skin Through Giveaway of 5,000 Differin Gel Products

• Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation¹
• Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle^1-3

• Six abstracts; including new phase 2 data for nemolizumab across PN and AD and new real-world evidence highlighting the PN disease burden being presented
• Prurigo nodularis: Rapid onset of action with over three times greater itch reduction versus placebo within 48 hours of the first dose and a four times greater improvement in sleep versus placebo as early as Day 4